Lantern Pharma (LTRN) Enterprise Value (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Enterprise Value came in at -$6.3 million in Q1 2026, up 66.47% YoY from -$3.8 million in Q1 2025, and up 12.62% on a QoQ basis from -$7.2 million in Q4 2025.
Lantern Pharma (LTRN) Enterprise Value (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Enterprise Value data on file, last reported at -$6.3 million in Q1 2026.
- Quarterly Enterprise Value rose 66.47% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.3 million (up 66.47% YoY) and the FY2025 annual result came in at -$7.2 million, up 68.7% from the prior year.
- Enterprise Value improved to -$6.3 million in Q1 2026, from -$7.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$1.8 million in Q4 2022 to a low of -$65.2 million in Q1 2022.
- A 5-year average of -$30.2 million and a median of -$29.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value soared 97.44% — and 2023, when it tumbled 2179.17%.
- Tracing LTRN's Enterprise Value over 5 years: stood at -$1.8 million in 2022, then plunged by 2179.17% to -$41.3 million in 2023, then soared by 44.02% to -$23.1 million in 2024, then soared by 68.7% to -$7.2 million in 2025, then rose by 12.62% to -$6.3 million in 2026.
- The last three Enterprise Value figures came in at -$6.3 million (Q1 2026), -$7.2 million (Q4 2025), and -$12.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 2.12 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | -6.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.32 Mn |
| Dec 31, 2025 | -7.24 Mn |
| Sep 30, 2025 | -12.36 Mn |
| Jun 30, 2025 | -14.46 Mn |
| Mar 31, 2025 | -18.86 Mn |
| Dec 31, 2024 | -23.12 Mn |
| Sep 30, 2024 | -28.05 Mn |
| Jun 30, 2024 | -31.79 Mn |
| Mar 31, 2024 | -36.69 Mn |
| Dec 31, 2023 | -41.30 Mn |
| Sep 30, 2023 | -44.93 Mn |
| Jun 30, 2023 | -28.96 Mn |
| Mar 31, 2023 | -33.02 Mn |
| Dec 31, 2022 | -1.81 Mn |
| Sep 30, 2022 | -57.83 Mn |
| Jun 30, 2022 | -62.15 Mn |
| Mar 31, 2022 | -65.22 Mn |
| Dec 31, 2021 | -70.73 Mn |
| Sep 30, 2021 | -73.83 Mn |
| Jun 30, 2021 | -79.59 Mn |